Plasma brain natriuretic peptide (BNP) level is known to reflect left ventricular wall stress (LVWS). Recent studies have shown that obese individuals have lower BNP levels. However, the usefulness of BNP level as a marker of LVWS in obese individuals remains unclear. This study examined whether BNP reflects LVWS even in obese individuals.
BRAIN natriuretic peptide (BNP) plays an important role in the homeostasis of body fluids and blood pressure, and is a well recognized diagnostic marker in heart failure.
1) The stretch of cardiomyocytes is the most important stimulus of BNP secretion. Many studies have shown that BNP levels increase in response to hemodynamic parameters, such as left ventricular end-diastolic pressure (LV-EDP), pulmonary capillary wedge pressure (PCWP), ejection fraction (EF), and LV volume. 2, 3) However, the individual differences in BNP levels are not clear and occasionally confuse clinicians. Recently, Iwanaga, et al provided further insight into the potential determinants of BNP secretion that may explain the observed heterogeneity in BNP levels between individuals with heart failure. They have showed that plasma BNP levels reflect LV end-diastolic wall stress (LV-EDWS) more strongly than any other parameter described so far. 4) Ikeda, et al have also reported that elevated plasma BNP levels in patients with aortic stenosis were highly correlated with LV end-systolic wall stress (LV-ESWS), which is a quantitative index of myocardial afterload. 5) The lower BNP levels in obese individuals have been a growing concern in recent years. Several recent studies in western countries found an inverse relationship between BNP and body mass index (BMI) in diverse populations, including healthy individuals. [6] [7] [8] [9] However, very few attempts have been made to explore the relationship between BNP and BMI in Japan. Moreover, whether plasma BNP levels strongly reflect LV wall stress in obese individuals remains unknown. This study examined the impact of LV wall stress on BNP levels in Japanese obese individuals.
Methods
Patient population: All individuals who underwent cardiac catheterization and echocardiographic examinations between April 2006 and March 2007 in our hospital and met the inclusion criteria were enrolled in the study. In all, 136 individuals (39 women and 97 men) who had mild chronic heart failure with New York Heart Association functional class I or II or an evaluation of angina pectoris were enrolled. All individuals were hemodynamically stable at the time of evaluation. The following exclusion criteria were used: renal insufficiency with serum creatinine levels ≥ 2.0 mg/dL, being on hemodialysis, and having hypertrophic cardiomyopathy. Blood was drawn in the fasting state for routine laboratory investigations.
BMI was calculated from body weight (kg) and height (m) in kg/m 2 . Based on the standards of the Japan Society for the Study of Obesity, the individuals were divided into two BMI categories: nonobese (BMI < 25, n = 78) and obese (BMI ≥ 25, n = 58). 10) We measured abdominal circumference at the umbilical level. On the basis of criteria for metabolic syndrome in Japan, hypertension, hyperglycemia, and dyslipidemia were defined as follows: hypertension (sys-tolic blood pressure ≥ 130 mmHg or diastolic pressure ≥ 85 mmHg or a history of antihypertensive therapy), hyperglycemia (fasting glucose level ≥ 110 mg/dL or a history of hyperglycemic therapy), dyslipidemia (plasma triglyceride levels ≥ 150 mg/dL or plasma high-density lipoprotein cholesterol < 40 mg/dL or a history of dyslipidemic therapy). Echocardiographic examination: All individuals underwent standardized two-dimensional guided B-mode echocardiography according to the recommendations of the American Society of Echocardiography using commercial ultrasound instrumentation (ACUSON Sequoia 512; Siemens, New York, and SSD-5500 Pro-Sound II; Aloka, Tokyo) with a 2.5-MHz sector transducer. The LV internal diameter, LV posterior wall thickness, and left atrial diameter were measured. The LV ejection fraction was calculated using the modified Simpson method. Echocardiographic pulse wave Doppler assessment of the mitral valve flow was used to assess diastolic LV compliance. From the trans-mitral pulsed-Doppler flow, we obtained peak E and A velocities, the ratio of early to late diastolic filling (E/A ratio), and the deceleration time of E wave (DcT). Cardiac catheterization: The left side of the heart was catheterized from the femoral or radial artery in all individuals to evaluate hemodynamic data. LV pressure was recorded with the catheter positioned in the left ventricle.
Estimated LV-EDWS and LV-ESWS:
Using the following formula, the LV-ED-WS and LV-ESWS were calculated from the echocardiographic data in combination with the LV pressure data:
LV Wall Stress = 0.334 × P × LVID/[PWT × (1 × PWT/LVID)], where P is the LV pressure, LVID is the LV internal diameter, and PWT is the posterior wall thickness. LV-wall stress was calculated at end-systole (ESWS) and end-diastole (EDWS). Statistics: The data are expressed as the mean ± standard error of the mean. The nonobese and obese groups were compared statistically using the t-test for continuous variables and the chi-square test for qualitative variables. Pearson's correlation coefficient was used to assess the association between BNP levels and hemodynamic variables. Values of P < 0.05 were considered to be statistically significant.
Results
The obese group included 58 individuals and the nonobese group consisted of 78 individuals (Table I) . The obese and nonobese groups did not differ significantly in age or gender, but BMI and abdominal circumstance were significantly higher in the obese group. The obese and nonobese groups did not differ significantly in hemoglobin concentration or serum creatinine level. No significant differences were observed in hypertension, hyperglycemia, prior myocardial in-farction, dilated cardiomyopathy, valvular heart disease, or atrial fibrillation, although there were significantly more individuals with dyslipidemia in the obese group than in the nonobese group. The use of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and diuretics was similar between the two groups. Table II shows various echocardiographic and hemodynamic parameters in both groups. No significant differences were observed in the extent of left ventricular hypertrophy between the two groups. The extent of diastolic dysfunction, which is based upon trans-mitral Doppler-flow parameters, was also the same in both groups. Furthermore, no significant differences were detected in LV end-diastolic pressure (obese group: 11.4 ± 0.6 mmHg versus nonobese group: 10.2 ± 0.6 mmHg, P = NS) or LV systolic pressure (obese 123.0 ± 2.7 mmHg versus nonobese 121.3 ± 2.6 mmHg, P = NS) between the two groups. Impact of obesity on BNP levels: No differences were found in LV-EDWS (obese group: 20.7 ± 1.3 kdyne/cm 2 versus nonobese group: 19.1 ± 1.3 kdyne/cm 2 , P = NS) or LV-ESWS (obese group: 101.2 ± 4.8 kdyne/cm 2 versus nonobese group: 103.9 ± 6.0 kdyne/cm 2 , P = NS) between the two groups ( Figure 1 ). Despite similar severity of the LV wall stress, the plasma BNP levels in the obese group 
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were significantly lower than in the nonobese group (obese group: 63.4 ± 9.0 pg/mL versus nonobese group: 123.6 ± 17.4 pg/mL, P < 0.01; Figure 2 ). Plasma BNP levels and LV wall stress: Subsequently, we analyzed the correlation between the plasma BNP levels and LV wall stress. For all individuals, significant correlations were observed between the plasma BNP levels and LV-EDWS (r = 0.27, P < 0.01) and LV-ESWS (r = 0.39, P < 0.01). In the nonobese group, the plasma BNP levels were positively correlated with LV-EDWS (r = 0.43, P < 0.01) and LV-ESWS (r = 0.46, P < 0.01; Figure 3A and C). In contrast, in the obese group, the plasma BNP levels were not significantly correlated with LV-EDWS (r = -0.09, P = NS) or LV-ESWS (r = 0.06, P = NS; Figure 3B and D). BNP was suppressed in the obese group irrespective of the increases in LV-EDWS and LV-ESWS. Relationship between BNP levels and adiponectin: To explore the mechanism for the suppressed BNP levels in obese individuals, the correlations of BNP with available biochemical markers were examined. However, no positive correlations were found, with the exception of adiponectin. Because plasma adi- 
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ponectin levels are known to be low in obese individuals, 11) we examined the correlation between BNP levels and plasma adiponectin concentrations in 66 individuals (20 women and 46 men). Consequently, a statistically significant correlation was found between adiponectin and BNP (r = 0.44, P < 0.01; Figure 4 ), implying that BNP or adiponectin might influence the plasma levels of the other.
Interestingly, despite the fact that BNP levels were significantly correlated with LV wall stress, plasma adiponectin levels were not significantly correlated with LV-EDWS (r = 0.15, P = NS) or LV-ESWS (r = 0.05, P = NS).
Discussion
Stretch of cardiomyocytes is known to be the most important stimulus of BNP regulation.
12) It is also believed that an increase in left ventricular wall stress is the key for release of BNP from the heart. This study investigated the impact of LV wall stress on plasma BNP levels in obese individuals.
We found that plasma BNP levels were significantly lower in Japanese obese individuals, a finding that is consistent with several studies conducted in western countries. This result suggests that the relationship between BNP and BMI was not affected by racial differences. Recently, Ikeda, et al reported that plasma BNP levels were correlated with LV-ESWS in patients with aortic stenosis.
5) Iwanaga, et al also reported that plasma BNP levels reflect LV-EDWS and LV-ESWS in heart failure patients, and the correlation between plasma BNP levels and LV-EDWS in particular was more robust than that between plasma BNP levels and LV-ESWS. 4) We also showed that plasma BNP levels were correlated positively with both LV-EDWS and LV-ESWS when we focused on nonobese individuals only ( Figure 3A and C) . However, the correlation coefficient between the plasma BNP levels and LV-EDWS in our study was almost the same as that between the plasma BNP levels and LV-ESWS. Compared with previous studies, the correlation of LV-EDWS with BNP was not good in our study. A possible explanation for the differences is that we focused on only subjects with mild heart failure in contrast to the previous study in which severe heart failure with NYHA III or IV was included.
Interestingly, despite the fact that LV-EDWS or LV-ESWS did not differ significantly between the obese and nonobese groups, plasma BNP levels were significantly lower in obese individuals compared to nonobese individuals. This is the first study to show that plasma BNP levels were suppressed irrespective of the increase in LV-EDWS and LV-ESWS in the obese group. It seems likely that this phenomenon contributes the interindividual variability of plasma BNP.
The mechanism of low BNP in obese individuals is not entirely clear. The factors controlling BNP levels in obesity are still poorly understood and controversial. Several explanations have been proposed for the lower BNP concentrations in obese individuals. First, Wang, et al proposed that increased clearance of circulating BNP occurs in obesity. 7) However, another group has revealed that NT-proBNP was also suppressed in obese individuals, 13) where NT-proBNP was not cleared by natriuretic peptide clearance receptors. This refutes the hypothesis that the negative correlation between BNP and BMI is due to the upregulation of natriuretic peptide clearance receptors in obesity. Second, the impaired synthesis and release of the BNP from cardiomyocytes in obese individuals may also be part of the mechanism underlying the reduced plasma BNP levels. 7) A recent article by Das, et al demonstrated that fat-free mass referred to as lean mass like muscle, was responsible for lower BNP levels in obese individuals. 14) They postulated that a substance produced in the lean mass may suppress either the synthesis or release of BNP from cardiomyocytes in obese individuals. Additional data are needed to clarify the relative importance of these mechanisms for reducing BNP levels in obese individuals.
Other previous studies have reported that plasma adiponectin levels were clearly and positively related with BNP concentrations. [15] [16] [17] We also found a significant correlation between BNP and adiponectin levels. Adiponectin is produced specifically by adipose tissue and is abundant in the circulation. Adiponectin concentrations decrease in obesity, and weight loss in subjects with obesity is associated with an increase in adiponectin concentrations. 18) Plasma adiponectin levels are elevated in patients with heart failure. 16) However, the cause of the increased adiponectin levels in patients with heart failure remains unclear. Moreover, the reasons for the positive relationship between BNP and adiponectin have not been fully elucidated. Recently, a novel lipolytic and po-tential lipid-mobilizing effect of BNP was identified. 19) Our data showed that LVWS of the nonobese group correlated well with BNP, but not with plasma adiponectin levels. These results imply that BNP or adiponectin might influence the synthesis or secretion of the other.
In conclusion, the results of our study suggest that BNP is not a useful biomarker for LVWS in obese individuals. Further study would be necessary to elucidate the mechanisms as to why BNP levels are suppressed and not correlated with left ventricular wall stress in obese individuals.
